title: Macrophage-based cell therapies: The long and winding road.
abstract: In the quest for better medicines, attention is increasingly turning to cell-based therapies. The rationale is that infused cells can provide a targeted therapy to precisely correct a complex disease phenotype. Between 1987 and 2010, autologous macrophages (MΦs) were used in clinical trials to treat a variety of human tumors; this approach provided a modest therapeutic benefit in some patients but no lasting remissions. These trials were initiated prior to an understanding of: the complexity of MΦ phenotypes, their ability to alter their phenotype in response to various cytokines and/or the environment, and the extent of survival of the re-infused MΦs. It is now known that while inflammatory MΦs can kill tumor cells, the tumor environment is able to reprogram MΦs into a tumorigenic phenotype; inducing blood vessel formation and contributing to a cancer cell growth-promoting milieu. We review how new information enables the development of large numbers of ex vivo generated MΦs, and how conditioning and gene engineering strategies are used to restrict the MΦ to an appropriate phenotype or to enable production of therapeutic proteins. We survey applications in which the MΦ is loaded with nanomedicines, such as liposomes ex vivo, so when the drug-loaded MΦs are infused into an animal, the drug is released at the disease site. Finally, we also review the current status of MΦ biodistribution and survival after transplantation into an animal. The combination of these recent advances opens the way for improved MΦ cell therapies.
authors.affiliation: The UC-Berkeley-UCSF Graduate Program in Bioengineering, University of California Berkeley, Berkeley 94720, USA.
authors.forename: Simon
authors.initials: S
authors.lastname: Lee
authors.affiliation: Department of Bioengineering, Therapeutic Sciences and Pharmaceutical Chemistry, University of California San Francisco, San Francisco 94143, USA.
authors.forename: Saul
authors.initials: S
authors.lastname: Kivimäe
authors.affiliation: Department of Bioengineering, Therapeutic Sciences and Pharmaceutical Chemistry, University of California San Francisco, San Francisco 94143, USA.
authors.forename: Aaron
authors.initials: A
authors.lastname: Dolor
authors.affiliation: The UC-Berkeley-UCSF Graduate Program in Bioengineering, University of California Berkeley, Berkeley 94720, USA; Department of Bioengineering, Therapeutic Sciences and Pharmaceutical Chemistry, University of California San Francisco, San Francisco 94143, USA. Electronic address: szoka@cgl.ucsf.edu.
authors.forename: Francis C
authors.initials: FC
authors.lastname: Szoka
mesh_terms: D000818:Animals; D060846:Cell Engineering; D016764:Cell Polarity / Q000276:immunology; D017690:Cell Transplantation / Q000379:methods*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D008264:Macrophages / Q000166:cytology / Q000276:immunology* / Q000637:transplantation*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
keywords: Cell polarization; Cell therapy; Drug delivery; Gene editing; Macrophages